Skip to main content

Table 1 Demographic and clinical characteristics of the study population

From: Participants’ awareness of ethical compliance, safety and protection during participation in pharmaceutical industry clinical trials: a controlled survey

Characteristic

Study population

T2DM

COPD

 

RA

 

HT

 

Cases

Controls

Cases

Controls

Cases

Controls

Cases

Controls

Cases

Controls

n = 604

n = 604

n = 151

n = 151

n = 151

n = 151

n = 151

n = 151

n = 151

n = 151

Age, mean ± SD (years)

54.9 ± 13.9

47.1 ± 15.5a

52.2 ± 12.8

46.6 ± 15.7a

60.3 ± 14.2

53.1 ± 16.7a

50.1 ± 13.4

41.6 ± 15.3a

56.8 ± 13.1

47 ± 12.1a

Age group, n (%)

  < 50 years

216 (35.8)

320 (53.0)a

68 (45.0)

83 (55.0)

31 (20.5)

57 (37.7)a

71 (47.0)

103 (68.2)a

46 (30.5)

77 (51.0)a

  > 50 years

388 (64.2)

284 (47.0)

83 (55.0)

68 (45.0)

120 (79.5)

94 (62.3)

80 (53.0)

48 (31.8)

105 (69.5)

74 (49.0)

Sex, n (%)

 Female

377 (62.4)

394 (65.2)

101 (66.9)

95 (62.9)

69 (45.7)

92 (60.9)b

126 (83.4)

110 (72.8)b

81 (53.6)

97 (64.2)

 Male

227 (37.6)

210 (34.8)

50 (33.1)

56 (37.1)

82 (54.3)

59 (39.1)

25 (16.6)

41 (27.2)

70 (46.4)

54 (35.8)

Years of education, n (%)

  < 9 years

363 (60.1)

341 (56.5)

90 (59.6)

82 (54.3)

89 (58.9)

76 (50.3)

90 (59.6)

85 (56.3)

94 (62.3)

98 (64.9)

  > 9 years

241 (39.9)

263 (43.5)

61 (40.4)

69 (45.7)

62 (41.1)

75 (49.7)

61 (40.4)

66 (43.7)

57 (37.7)

53 (35.1)

Health care, n (%)

 Yes

476 (78.8)

453 (75)

122 (80.8)

118 (78.1)

116 (76.8)

121 (80.1)

112 (74.2)

116 (76.8)

126 (83.4)

98 (64.9)a

 No

128 (21.2)

151 (25)

29 (19.2)

33 (21.9)

35 (23.2)

30 (19.9)

39 (25.8)

35 (23.2)

25 (16.6)

53 (35.1)

Previous clinical trial participation (case group only), n (%)

 One

395 (65.4)

 

89 (58.9)

 

89 (58.9)

 

119 (78.8)

 

98 (64.9)

 

 Two to three

196 (32.5)

 

60 (39.7)

 

56 (37.1)

 

28 (18.5)

 

52 (34.4)

 

Three to six

10 (1.7)

 

2 (1.3)

 

5 (3.3)

 

2 (1.3)

 

1 (0.7)

 

 More than six

3 (0.5)

 

0 (0)

 

1 (0.7)

 

2 (1.3)

 

0 (0)

 
  1. aP ≤ 0.001; bP ≤ 0.05
  2. T2DM Type 2 diabetes mellitus, COPD chronic obstructive pulmonary disease, RA rheumatoid arthritis, HT hypertension